Vaccine Update
On Monday 7/20, Phase II study results for a vaccine developed by Oxford were published in *The Lancet*. This trial conducted in 602 health volunteers compared two at different doses with placebo. For the 382 vaccine exposed individuals, 93% developed T-cell responses to the virus. Adverse events were reported by > 70% of subjects receiving vaccine and were most commonly, fatigue, headache and fever. Another promising early vaccine study and we continue to await further data from candidate vaccines as many move into Phase III trials.

*The article and corresponding comment can be found at these links:*
[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext)

**COMMENT**
*Encouraging results from phase 1/2 COVID-19 vaccine trials*

Treatment Updates
On Monday, July 20, 2020, a press release was issued by Synairgen with preliminary results of a unique inhaled formulation of interferon beta (SNG-001) used in hospitalized patients with COVID-19. The preliminary results reported a 79% reduction in developing severe disease compared to placebo. As with other similar reports, we eagerly await the opportunity to review full data in order to assess the potential role of this new formulation in therapy. The press release and a link to the press conference can be found here: [https://www.synairgen.com/](https://www.synairgen.com/)

New Literature This Week
**Hydroxychloroquine**
There was a study published this week in the *New England Journal of Medicine* regarding hydroxychloroquine. Given that hydroxychloroquine is no longer recommended as a treatment strategy, we will continue to update the hydroxychloroquine study table, and will only include literature summaries if findings differ from current consensus statements on the role of this agent in therapy of COVID-19.

Updates being added this week include the following studies:

- Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
- Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 Among Healthcare Workers: Initial Experience from India
Treatment Summary Tables
*The remdesivir summary table with the information of published studies to date can be found at this link*: https://dason.medicine.duke.edu/summary-recent-clinical-data-use-remdesivir-covid-19

*The hydroxychloroquine summary table is available at this link*: https://dason.medicine.duke.edu/summary-recent-clinical-data-use-hydroxychloroquine-and-chloroquine-covid-19

*The tocilizumab summary table with the information of published studies to date can be found at this link*: https://dason.medicine.duke.edu/summary-recent-clinical-data-use-tocilizumab-covid-19

Updated FAQs
All FAQs available here: https://dason.medicine.duke.edu/covid-19-novel-coronavirus-resources

Updated this week:
Should antibiotic therapy be continued in patients diagnosed with COVID-19? (July 24, 2020)
Should NSAIDS be administered to patients who have COVID-19? (July 24, 2020)
What is the role of vitamin C in the prevention and treatment of COVID-10? (July 20, 2020)
Zinc supplementation, immunity and COVID-19 (July 20, 2020)